相关实验视频

Updated: Mar 3, 2026

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Multi-photon Imaging of Tumor Cell Invasion in an Orthotopic Mouse Model of Oral Squamous Cell Carcinoma

Published on: July 25, 2011

通过综合生物信息学和初步实验,TNFRSF10B是口腔状细胞癌的治疗标

Yingshun Yang¹, Zhizheng Zhuang², Yan Hu²

¹Department of Oral and Maxillofacial Surgery, Hebei Eye Hospital, Xingtai, China.

Technology in cancer research & treatment

|March 2, 2026

概括

瘤亡因子受体超级家族10B成员 (TNFRSF10B) 通过损害亡来驱动口腔癌的进展. 向TNFRSF10B可能会恢复细胞亡,并使口腔状细胞癌 (OSCC) 的精确治疗成为可能.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

口腔状细胞癌 (OSCC) 的发展受到亡调节者的关键影响.
瘤亡因子受体超级家族成员10B (TNFRSF10B) 被确定为OSCC亡调节中的关键参与者.

研究的目的:

确定调节OSCC进展的关键基因.
调查TNFRSF10B在OSCC发展,预后以及作为潜在的治疗点中的作用.

主要方法:

差异基因表达分析和加权基因共同表达网络分析.
拉索回归,考克斯建模,并在癌症基因组图谱 (TCGA) 和临床样本中进行验证.
蛋白质-蛋白质相互作用网络的构建,基因本体学 (GO) 和基因和基因组的京都百科全书 (KEGG) 路径分析,以及体外siRNA介导的基因敲除实验.

主要成果:

TNFRSF10B被确定为与不利的OSCC预后显著相关的核心基因,表现出强大的诊断能力.
过度表达TNFRSF10B与晚期临床阶段,结节转移,化学抵抗相关,并与外部和死核性亡途径有关.
通过调节Bax,Bcl-2和Caspase-3/PARP激活来抑制TNFRSF10B抑制细胞活力和诱导细胞亡.

结论:

TNFRSF10B通过抑制亡来促进OSCC的进展,其过度表达与预后不佳有关.
TNFRSF10B代表了一个潜在的诊断生物标志物和OSCC的治疗点.
准TNFRSF10B有望恢复亡并推进OSCC的精密疗法.

关键词:

在TNFRSF10B中.灭症 (apoptosis) 是一种死亡的过程.口腔状细胞癌的癌症.治疗向的治疗向

更多相关视频

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity

In Vivo CRISPR/Cas9 Screening to Simultaneously Evaluate Gene Function in Mouse Skin and Oral Cavity

Published on: November 2, 2020

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...